The Food and Drugs Administration is expanding the regulatory agency’s investigation into impurities in U.S. generic drugs beyond a class of hypertension drugs known as angiotensin II receptor blockers (ARBs).

The U.S. Food and Drug Administration will temporarily allow certain manufacturers to sell blood pressure medications containing specified levels of a probable cancer-causing impurity in order to maintain adequate supplies of the drug.

A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd. will recall 80 lots of medicines containing the blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.